Additionally, diminished ALDH2 expression is associated with lower survival rates in skin cutaneous melanoma (SKCM), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), KIRC, KIRP, brain low-grade glioma (LGG), LIHC, and mesothelioma (MESO). Here, ALDH2 is linked to cutaneous melanoma.